VenaSeal maintains safety and efficacy at extended five-year follow-up - Venous News

VenaSeal maintains safety and efficacy at extended five-year follow-up  Venous News

The first-ever 60-month data on Medtronic's VenaSeal closure system were presented on Tuesday, indicating that at five years, treatment with the cyanoacrylate ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more